<DOC>
	<DOCNO>NCT02644499</DOCNO>
	<brief_summary>This study conduct find well patient rheumatoid arthritis ( RA ) respond disease-modifying antirheumatic drug ( DMARDs ) . RA chronic inflammatory arthritis , lead joint damage &amp; disability treat properly . A DMARD use treat RA slow prevents joint damage , oppose relieve pain inflammation painkiller . The study conduct Department Clinical Immunology , JIPMER ( Jawaharlal Institute Postgraduate Medical Education &amp; Research ) . Patients receive either single DMARD ( Methotrexate ) combination DMARDs therapy ( Methotrexate + Leflunomide + Hydroxychloroquine ) . During treatment course , routine blood investigation carry monitor treatment response side effect .</brief_summary>
	<brief_title>Comparison Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy Early Rheumatoid Arthritis</brief_title>
	<detailed_description>Patients age ≥18 year , fulfil 2010 ACR EULAR criterion RA ( symptom duration less one year ) &amp; moderate severe disease activity ( DAS28≥3.2 ) invite participate . After provide write informed consent , eligible patient stratify two group . Block randomization do generate random allocation sequence . Treatment Group I treat Methotrexate ( MTX ) monotherapy Treatment Group II treat Methotrexate + Leflunomide ( LEF ) + Hydroxychloroquine ( HCQ ) combination therapy . Concurrent treatment non-steroidal anti-inflammatory drug adequate dose oral low dose Glucocorticoids ( GC ) ( max : 15 mg/d ) allow study . DMARD dosages use : MTX 25 mg/week orally ( dosage 6 week ) , LEF 20 mg/day ( dosage 2 week ) HCQ 400 mg/day . GCs give oral taper scheme . All patient prescribe folic acid ( 10 mg/week ) MTX prescription .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>1 . Age &gt; 18 year satisfy 2010 ACR ( American college rheumatology ) EULAR criterion RA 2 . Arthritis one joint ( ) 3 . Symptom duration &lt; 1 year 4 . DMARD naive 5 . Patients moderate severe disease activity ( DAS28 ≥3.2 ) 1 . Disease Remission/inactive disease ( DAS28 criterion ) 2 . End stage disease ( deform fix joint ) 3 . Patients vasculitis severe extraarticular feature 4 . Contraindications DMARD therapy ( Chronic Alcoholism , Chronic liver disease , Evidence acute/chronic infection , Chronic kidney disease , Patients leucopenia ( &lt; 3.0×109/l ) , thrombocytopenia ( &lt; 150×109/l ) , aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &gt; 2× upper normal value creatinine level &gt; 150 μmol/l ) 5 . Pregnant , lactate female inadequate contraception 6 . Patients unable come regular follow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>